Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress

Blood

Volumn 123, Issue 17, 2014, Pages 2715-2721

  Da, Qi ^a   Behymer, Molly ^a   Correa, Juliana I ^a   Vijayan, K Vinod ^a,b   Cruz, Miguel A ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; GLYCOPROTEIN IB ALPHA; UNCLASSIFIED DRUG; VIMENTIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR A1; IMMUNOGLOBULIN G; THROMBIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; HEK293 CELL LINE; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SHEAR STRESS; THROMBOCYTE ADHESION; THROMBOCYTE MEMBRANE; WILD TYPE; ANIMAL; CYTOSKELETON; DOSE RESPONSE; MECHANICAL STRESS; METABOLISM; PROTEIN BINDING; SHEAR STRENGTH; THROMBOCYTE;

ANIMALS; BLEEDING TIME; BLOOD PLATELETS; CYTOSKELETON; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; MICE; PLATELET ADHESIVENESS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROTEIN BINDING; SHEAR STRENGTH; STRESS, MECHANICAL; VIMENTIN; VON WILLEBRAND FACTOR;

EID: 84902097147     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-530428     Document Type: Article

References (52)

1. Alevriadou BR, Moake JL, Turner NA, et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood. 1993;81(5):1263-1276. (Pubitemid 23067364)
2. Bonnefoy A, Vermylen J, Hoylaerts MF. Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis. Expert Rev Cardiovasc Ther. 2003;1(2):257-269.
3. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008;28(3):403-412.
4. Savage B, Saldívar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84(2):289-297. (Pubitemid 26040846)
5. Bonthron DT, Handin RI, Kaufman RJ, et al. Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature. 1986;324(6094):270-273. (Pubitemid 17180458)
6. Sixma JJ, Schiphorst ME, Verweij CL, Pannekoek H. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem. 1991;196(2):369-375.
7. Lankhof H, Damas C, Schiphorst ME, et al. von Willebrand factor without the A2 domain is resistant to proteolysis. Thromb Haemost. 1997;77(5):1008-1013. (Pubitemid 27239131)
8. Cruz MA, Yuan H, Lee JR, Wise RJ, Handin RI. Interaction of the von Willebrand factor (vWF) with collagen. Localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides. J Biol Chem. 1995;270(18):10822-10827.
9. Auton M, Sowa KE, Smith SM, Sedlák E, Vijayan KV, Cruz MA. Destabilization of the A1 domain in von Willebrand factor dissociates the A1A2A3 tridomain and provokes spontaneous binding to glycoprotein Ibalpha and platelet activation under shear stress. J Biol Chem. 2010;285(30):22831-22839.
10. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113(3):526-534.
11. Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension. Blood. 2003;101(7):2637-2645. (Pubitemid 36857624)
12. Azuma H, Sugimoto M, Ruggeri ZM, Ware J. A role for von Willebrand factor proline residues 702-704 in ristocetin-mediated binding to platelet glycoprotein Ib. Thromb Haemost. 1993;69(2):192-196. (Pubitemid 23041192)
13. Ruggeri ZM. Von Willebrand's disease and the mechanisms of platelet function. Ciba Found Symp. 1995;189:35-45.
14. Matsushita T, Sadler JE. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-toalanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J Biol Chem. 1995;270(22):13406-13414.
15. Miyata S, Ruggeri ZM. Distinct structural attributes regulating von Willebrand factor A1 domain interaction with platelet glycoprotein Ibalpha under flow. J Biol Chem. 1999;274(10):6586-6593. (Pubitemid 29111076)
16. Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI. Mapping the glycoprotein Ib-binding site in the von willebrand factor A1 domain. J Biol Chem. 2000;275(25):19098-19105. (Pubitemid 30422878)
17. Doggett TA, Girdhar G, Lawshé A, et al. Selectinlike kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIb(α)-vWF tether bond. Biophys J. 2002;83(1):194-205. (Pubitemid 34694731)
18. Yago T, Lou J, Wu T, et al. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest. 2008;118(9):3195-3207.
19. Auton M, Sowa KE, Behymer M, Cruz MA. N-terminal flanking region of A1 domain in von Willebrand factor stabilizes structure of A1A2A3 complex and modulates platelet activation under shear stress. J Biol Chem. 2012;287(18):14579-14585.
20. Ise H, Kobayashi S, Goto M, et al. Vimentin and desmin possess GlcNAc-binding lectin-like properties on cell surfaces. Glycobiology. 2010;20(7):843-864.
21. Moisan E, Girard D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J Leukoc Biol. 2006;79(3):489-498. (Pubitemid 44831226)
22. Päll T, Pink A, Kasak L, et al. Soluble CD44 interacts with intermediate filament protein vimentin on endothelial cell surface. PLoS ONE. 2011;6(12):e29305.
23. Xu B, deWaal RM, Mor-Vaknin N, Hibbard C, Markovitz DM, Kahn ML. The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. Mol Cell Biol. 2004;24(20):9198-9206. (Pubitemid 39313921)
24. Zou Y, He L, Huang SH. Identification of a surface protein on human brain microvascular endothelial cells as vimentin interacting with Escherichia coli invasion protein IbeA. Biochem Biophys Res Commun. 2006;351(3):625-630. (Pubitemid 44708855)
25. Podor TJ, Singh D, Chindemi P, et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem. 2002;277(9):7529-7539. (Pubitemid 34953151)
26. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A. 1990;87(16):6306-6310.
27. Martin C, Morales LD, Cruz MA. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. J Thromb Haemost. 2007;5(7):1363-1370. (Pubitemid 46965360)
28. Smith C, Estavillo D, Emsley J, Bankston LA, Liddington RC, Cruz MA. Mapping the collagen-binding site in the I domain of the glycoprotein Ia/IIa (integrin a(2)b(1)). J Biol Chem. 2000;275(6):4205-4209. (Pubitemid 30094656)
29. Cruz MA, Chen J, Whitelock JL, Morales LD, López JA. The platelet glycoprotein Ib-von Willebrand factor interaction activates the collagen receptor alpha2beta1 to bind collagen: activation-dependent conformational change of the alpha2-I domain. Blood. 2005;105(5):1986-1991. (Pubitemid 40731782)
30. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol. 2003;5(1):59-63. (Pubitemid 36054330)
31. Guerrero JA, Shafirstein G, Russell S, et al. In vivo relevance for platelet glycoprotein Ibalpha residue Tyr276 in thrombus formation. J Thromb Haemost. 2008;6(4):684-691. (Pubitemid 351404937)
32. Gushiken FC, Hyojeong H, Pradhan S, et al. The catalytic subunit of protein phosphatase 1 gamma regulates thrombin-induced murine platelet alpha (IIb)beta(3) function. PLoS ONE. 2009;4(12):e8304.
33. Coburn LA, Damaraju VS, Dozic S, Eskin SG, Cruz MA, McIntire LV. GPIba-vWF rolling under shear stress shows differences between type 2B and 2M von Willebrand disease. Biophys J. 2011;100(2):304-312.
34. Vasudevan S, Roberts JR, McClintock RA, et al. Modeling and functional analysis of the interaction between von Willebrand factor A1 domain and glycoprotein Ibalpha. J Biol Chem. 2000;275(17):12763-12768. (Pubitemid 30241430)
35. Chen J, Ling M, Fu X, López JA, Chung DW. Simultaneous exposure of sites in von Willebrand factor for glycoprotein Ib binding and ADAMTS13 cleavage: studies with ristocetin. Arterioscler Thromb Vasc Biol. 2012;32(11):2625-2630.
36. Ivaska J, Pallari HM, Nevo J, Eriksson JE. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res. 2007;313(10):2050-2062. (Pubitemid 46842979)
37. Hasan AA, Zisman T, Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci U S A. 1998;95(7):3615-3620. (Pubitemid 28173176)
38. Perides G, Harter C, Traub P. Electrostatic and hydrophobic interactions of the intermediate filament protein vimentin and its amino terminus with lipid bilayers. J Biol Chem. 1987;262(28):13742-13749.
39. Nishimura N, Balch WE. A di-acidic signal required for selective export from the endoplasmic reticulum. Science. 1997;277(5325):556-558. (Pubitemid 27369002)
40. Escolar G, Lopez-Vilchez I, Diaz-Ricart M, White JG, Galan AM. Internalization of tissue factor by platelets. Thromb Res. 2008;122(Suppl 1):S37-S41.
41. Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res. 2007;13(18 Pt 1):5341-5347. (Pubitemid 47510358)
42. Chi F, Jong TD, Wang L, et al. Vimentin-mediated signalling is required for IbeA+ E. coli K1 invasion of human brain microvascular endothelial cells. Biochem J. 2010;427(1):79-90.
43. Kim H, Nakamura F, Lee W, Hong C, Pérez-Sala D, McCulloch CA. Regulation of cell adhesion to collagen via beta1 integrins is dependent on interactions of filamin A with vimentin and protein kinase C epsilon. Exp Cell Res. 2010;316(11):1829-1844.
44. Lahat G, Zhu QS, Huang KL, et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS ONE. 2010;5(4):e10105.
45. Cruz MA, Whitelock J, Dong JF. Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate. Thromb Haemost. 2003;90(6):1204-1209. (Pubitemid 38004445)
46. Whitelock JL, Nolasco L, Bernardo A, Moake J, Dong JF, Cruz MA. ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. J Thromb Haemost. 2004;2(3):485-491. (Pubitemid 40185662)
47. Dong JF, Whitelock J, Bernardo A, Ball C, Cruz MA. Variations among normal individuals in the cleavage of endothelial-derived ultra-large von Willebrand factor under flow. J Thromb Haemost. 2004;2(8):1460-1466. (Pubitemid 40186146)
48. Krishnan A, Lopes RD, Alexander JH, Becker RC, Goldstein LB. Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician. J Thromb Thrombolysis. 2010;29(3):368-377.
49. Terraube V, Marx I, Denis CV. Role of von Willebrand factor in tumor metastasis. Thromb Res. 2007;120(Suppl 2):S64-S70. (Pubitemid 350101773)
50. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033-3046.
51. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol. 2002;3(7):425-430. (Pubitemid 36958273)
52. Lenting PJ, Casari C, Christophe OD, Denis CV. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost. 2012;10(12):2428-2437.